THE UNIVERSITY OF MICHIGAN

Regents Communication

ACTION REQUEST

Subject: Report of Faculty Retirement
Action Requested: Adoption of Retirement Memoir

Terry J. Smith, M.D., Frederick G.L. Huetwell Professor of Ophthalmology and Visual Sciences, professor of ophthalmology and visual sciences, and professor of internal medicine in the Medical School, retired from active faculty status on December 31, 2020.

Dr. Smith received his undergraduate education from Tulane University and his M.D. degree from the University of Missouri, Columbia in 1975. He completed additional training at the University of Illinois, Chicago; the Sinai Hospital in Baltimore, Maryland; the University of California, San Francisco; Columbia University College of Physicians and Surgeons; and the University of Chicago’s Pritzker School of Medicine. After serving at a number of leading institutions, he joined the University of Michigan faculty as a professor in 2009.

Dr. Smith was internationally acclaimed for his groundbreaking and paradigm-shifting basic, translational, and clinical research into the pathogenesis and treatment of thyroid-associated ophthalmopathy (TAO), a disfiguring and potentially blinding autoimmune manifestation of Graves’ disease. He was continuously supported since 1983 as the principal investigator by a Merit Review Grant from the VA and then by up to three simultaneous NIH R01 grants (all as the PI). He was the first to identify the role of CD34+ fibrocytes as the critical infiltrating cell-type in TAO and to discover that these cells promiscuously express many autoantigens underlying not only Graves’ disease but other diseases as well, including Type 1 diabetes mellitus and multiple sclerosis. He was the first to implicate the insulin-like growth factor I receptor in TAO and propose that targeting this receptor represented an effective therapy for the condition. His molecular studies provided him with the rationale for leading the organization of two placebo-controlled, multicenter clinical trials of teprotumumab, a β-arrestin-biased agonist inhibitor of IGF-IR in severe TAO. Both trials, published in the New England Journal of Medicine, demonstrated that teprotumumab was remarkably effective and had a very favorable side effect profile. Those results culminated in teprotumumab being approved in January 2020 by the FDA as the first medical therapy registered for TAO. The introduction of this drug, marketed as Tepezza, to the marketplace earlier this year has been widely hailed as “miraculous” and a clinical care-altering addition to the treatment options of patients with TAO. Dr. Smith published more than 250 peer-reviewed scientific and review articles and was awarded five patents for his scientific discoveries. Dr. Smith served as chief scientific and medical directors of the National Graves’ Disease Foundation for nearly 20 years.

The Regents now salute this distinguished faculty member by naming Terry J. Smith, professor emeritus of ophthalmology and visual sciences and professor emeritus of internal medicine.

Requested by:

Sally J. Churchill, J.D.
Vice President and Secretary of the University

February 2021